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Abstract 
The accumulation of microtubule-associated protein tau into fibrillar aggregates is 
the hallmark of Alzheimer’s disease and other neurodegenerative disorders, collectively 
referred to as tauopathies. Fibrils can propagate from one cell to the next and spread 
throughout the brain. However, a study shows that only small aggregates can be taken up 
by cultured neuronal cells. The mechanisms that lead to the breakage of fibrils into 
smaller fragments remain unknown. In yeast, the AAA+ chaperone HSP104 processes 
the reactivation of protein aggregates and is responsible for fragmentation of fibrils. This 
study focused on investigating the effects of molecular chaperones on tau fibrils and 
using HSP104 as a model system to test whether we can monitor fibril fracturing. 
The assays used to detect the chaperone’s actions on tau utilized acrylodan 
fluorescence, thioflavin T fluorescence, and sedimentation. Tau fibrils were either formed 
with a cofactor, heparin, to accelerate assembly or without a cofactor. In the process of 
investigating the effects of HSP104 on tau fibrils, this study established an assay to 
determine the effects of breakage on the seeding properties of tau fibrils. Our findings 
demonstrated that the sonication of tau fibrils produces smaller fragments (seeds) that 
accelerate the conversion of monomeric tau into fibrils. The use of this assay with 
HSP104 provided evidence that HSP104 inhibits the elongation of tau fibrils. Indeed, 
HSP104 inhibits the aggregation of soluble tau into aggregates. However, tau fibril 
breakage and dissociation were not observed with HSP104, either alone or in 
	   iii 
combination with co-chaperones (HSP70 and HSP40). Our findings provide insights into 
the seeding properties of tau fibrils, and suggest that fragmentation is a critical part of tau 
assembly. This knowledge should be valuable for understanding tau fibril aggregation 
and propagation in the brain, which is necessary to identify new treatments for 
neurodegenerative diseases. 
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Chapter 1: Introduction 
1.1 Protein misfolding and diseases 
Proteins are one of the primary biological molecules for life and have several 
cellular functions. Most proteins fold into a unique three-dimensional structure in order to 
perform their functions (Hartl & Hayer-Hartl, 2009; Anfinsen, 1973). In vitro, several 
proteins have demonstrated the capability to fold spontaneously (Jackson, 1998). Folding 
is achieved when a protein reaches the most thermodynamically stable state; however, the 
protein may fold incorrectly. The failure of the cell to remove these misfolded proteins 
might lead to the accumulation of non-functional and toxic complexes known as 
aggregates (Murphy & Kendrick, 2007). During the folding process, proteins pass 
through many partially folded intermediates. Indeed, the cytosol is crowded since it 
contains high concentrations of proteins, nucleic acids and macromolecules. This 
crowded environment (approximately 300-400 mg/ml) enhances the propensity of protein 
aggregation (Ellis & Minton, 2006). The misfolding of proteins is the initial step for 
many diseases relating to conformational damage that are called protein conformational 
disorders (Soto, 2001). Neurodegenerative diseases are examples of conformational 
disorders that include Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral 
sclerosis (ALS), prion diseases and others (Ross & Poirier, 2004; Gregersen et al., 2006). 
Cells have many mechanisms to clear misfolded proteins, including repair via refolding 
or breakage of aggregates. One of the known classes of proteins that cells utilize to clear 
	   2 
aggregates are the molecular chaperone proteins which also assist the folding of newly 
synthesized proteins (Muchowski, 2002). Cells also possess a ubiquitin proteasome 
system that breaks down protein aggregates (Lecker, Goldberg, & Mitch, 2006). Studying 
the misfolding and aggregation of proteins is key to better understanding these diseases 
and discovering a treatment for them.  
1.1.1 Alzheimer’s disease 
The treatment of neurodegenerative diseases is a significant challenge faced by 
scientists in recent decades. All of these diseases share characteristics of a protein folding 
disorder that leads to either neuron dysfunction or death (Rubinsztein, 2006). Since the 
neurons cannot be replaced, damage of these cells causes permanent brain defects 
(Morrison & Hof, 1997). Nearly 70% of people with dementia suffer from Alzheimer’s 
disease. In 2014, the number of patients with Alzheimer’s disease in the United States 
was 5.2 million. Ninety-six percent of these subjects were 65 years or older, with 
approximately 200,000 others suffering from an early onset of Alzheimer’s disease 
(Hebert et al., 2013). It has been suggested that by 2050 as many as 13.8 million will be 
stricken unless Alzheimer’s disease becomes treatable (Hebert et al., 2013; Brookmeyer 
et al.,2007). Alzheimer’s disease is the most common form of dementia that affects the 
patient’s memory and thinking, eventually leading to death. Although there is no cure for 
Alzheimer’s disease yet, there is modest optimism about the future of treatment for 
Alzheimer’s disease, due to huge progress in recent research (Huang & Mucke, 2012). 
1.2 Amyloid and pathologies  
The assembly of proteins generates ordered and disordered aggregates, depending 
on the protein’s sequence and environment (Fink, 1998). Disordered aggregates are 
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known as amorphous aggregates that correlate with various human diseases such as ALS 
(Kim, H et al., 2013; Xu et al., 2011; Wang et al., 2010). Ordered harmful fibrillar 
aggregates called amyloid fibrils are also formed (Dobson, 2003). Amyloid fibrils are 
highly structured and stable aggregates. A cross-β structure is considered as a hallmark of 
amyloid structure, in which β-strands run perpendicular and the β- sheet is parallel to the 
fibril axis (Sunde et al., 1997; Makin & Serpell, 2005). The amyloid fibrils are very 
stable, and resistant to heat, proteolysis and detergents (Vashist, Cushman, & Shorter, 
2010). Amyloids act as a template for seeding of native proteins that can be recruited 
onto fibrils (Jarrett & Lansbury Jr, 1993). Amyloid fibrils have the ability to bind to some 
dyes such as thioflavin T imparting an enhanced fluorescence (Levine, 1999). For this 
reason, thioflavin T is used to detect amyloid fibrils. 
The formation of fibrils is described by nucleation dependent polymerization. 
(Friedhoff et al., 1998; Jarrett & Lansbury Jr, 1993). Nucleation involves conversion of 
monomers into nuclei, which individual monomers can grow onto. A previous study 
described the presence of fibril fragmentation as secondary pathway for fibril growth 
(Ramachandran & Udgaonkar, 2012). Fragmentation leads to form additional nucleation 
competent species. Once the nuclei are formed, subsequent addition of monomers will 
proceed to elongate fibrils (Fändrich, 2007; Harper & Lansbury Jr, 1997). This 
mechanism is followed by many amyloids such as tau (Friedhoff et al., 1998). In vitro, 
sonication causes breakage of amyloid fibrils generating small fragments (seeds) 
(Muchowski et al., 2000; Rochet & Lansbury Jr, 2000). Since the breakage of amyloid 
increases the number of ends that monomers grow on, these seeds enhance protein 
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aggregation (Figure 1.1) (Guo & Lee, 2011; Harper and Lansbury Jr, 1997; Eichner & 
Radford, 2011; Ohhashi et al., 2005).  
 
 
 
 
Figure 1.1: Sonication effects on the seeding properties of amyloid fibrils. The 
breakage of amyloid fibrils by sonication leads to the fragmentation of fibrils into smaller 
aggregates (seeds). This increases the number of fibril ends, onto which monomers can 
grow, and hence accelerates fibril formation (Collinge & Clarke, 2007). 
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Amyloidosis refers to a group of diseases in which amyloid fibrils accumulate in 
organ or tissue (Chiti & Dobson, 2006). This accumulation occurs in many organs 
including the kidneys, heart and brain (Shah, Inoue, & Mehra, 2006; Dember, 2006; Iwai 
et al., 1995). In amyloidosis, each disease has a different protein that aggregates. 
However, all these protein aggregates represent fibrillar morphology and share an 
amyloid structure (Chiti & Dobson, 2006). Alzheimer’s disease is characterized by 
extracellular deposits of beta amyloid (Aβ) peptides. The extracellular accumulation of 
Aβ aggregates leads to the formation of amyloid plaques (Spillantini & Goedert, 2013). 
Aβ is a protein fragment consisting of 40 or 42 amino acids (Hasegawa, Smith, & 
Goedert, 1998). It is produced due to cleavage of the amyloid precursor protein (APP), 
which is a transmembrane protein whose function is still unknown (Spillantini & 
Goedert, 2013). Besides Aβ, Alzheimer’s disease is also characterized by intracellular 
deposits of microtubule associated protein tau (Spillantini & Goedert, 2013). 
1.3 Tau protein  
1.3.1 Overview: (discovery, structure, function) 
Tau protein was discovered and isolated from porcine brain in 1975 by Marc 
Kirschner's laboratory while they were studying cell microtubule assembly and 
disassembly (Weingarten et al., 1975). Tau is stable and resistant to heat and acid 
treatment without losing its function (Weingarten et al., 1975; Spillantini & Goedert, 
2013). Tau is a natively unfolded protein and mostly presents in the axons of nerve cells, 
although some studies show the presence of tau in dendrites (Ittner et al., 2010; 
Trojanowski et al., 1989). The normal function of tau is to stabilize microtubules in the 
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neuron cytoplasm. Tau plays a role in the initiation, formation, and elongation of 
microtubules (Drubin et al., 1985; Witman et al., 1976). Tau affinity toward microtubules 
is regulated by phosphorylation. Tau is a highly soluble protein. However, 
hyperphosphorylated tau becomes unable to bind to microtubules (Buee et al., 2010; 
Bramblett et al., 1993). Therefore, the concentrations of tau monomer increase in the 
cytosol causing aggregation into neurofibrillary tangles (NFTs), which are bundles of 
filaments that have a cross-β structure (Berriman et al., 2003). In Alzheimer’s disease, 
tau is hyperphosphorylated and forms either paired helical filaments (PHFs) or straight 
filaments (SFs) (Berriman et al., 2003). PHF and SF are the predominant aggregates of 
tau that are observed in Alzheimer’s disease, although there are some other morphologies 
of tau filaments found in other tauopathies (Crowther & Goedert, 2000). 
MAPT is the gene that encodes tau, and it consists of 16 different exons. Exons 
E2, E3 and E10 are responsible for the variation in tau isoforms (Lee, Goedert, & 
Trojanowski, 2001; Spillantini & Goedert, 2013). Upon alternative splicing of mRNA, 
six tau isoforms are produced. The tau isoforms differ based on the presence or absence 
of 29- or 58 amino acids in the N-terminal region (Figure 1.2 A). In addition, exon 10 is 
responsible for encoding 31-amino acid and the second of four possible microtubule 
binding domains that are located near the C-terminal end. The inclusion or the exclusion 
of exon 10 produces forms that can be categorized into two groups: three-repeat tau (3R) 
and four-repeat tau (4R) (Figure 1.2 A) (Lee, Goedert, & Trojanowski, 2001). The 
longest tau isoform has 441 amino acids whereas the shortest one has 352 amino acids. 
Both the 3R and 4R isoforms are expressed in a healthy adult human brain in an equal 
ratio (Goedert et al., 1989). Tau monomers assemble through the repeat domains forming 
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a protease resistant core (Wischik et al., 1988b). The C-and N-terminal regions of tau 
filaments remain unstructured forming a fuzzy coat (Wischik et al., 1988a; Wegmann et 
al., 2013). This region was reported to inhibit aggregation (Barghorn & Mandelkow, 
2002). The removal of the N- and C-termini produces the 4R and 3R constructs K18 and 
K19 (Barghorn & Mandelkow, 2002) (Figure 1.2 B).  
 
 
 
 
 
 
Figure 1.2: Tau isoforms and truncated constructs. (A) The six tau isoforms differ by 
the presence or absence of zero, one or two inserts (N) (dark squares) in the N-terminal 
region and the inclusion or exclusion of the second microtubule binding repeat in the C-
terminal region (labeled as 2) which produces isoforms with four (4R) or three (3R) 
microtubule binding repeats. (B) The truncated constructs K18 (4R) and K19 (3R) are 
derived from the microtubule binding repeat region of full-length tau in addition to three 
residues at the C-termini.   
(B) 
(A) 
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1.3.2 Tauopathies 
 Tauopathies are classified as a group of neurodegenerative diseases, including 
Alzheimer’s disease, progressive supranuclear palsy, Picks’s disease, coricobasal 
degeneration, and Down’s syndrome (Spillantini & Goedert, 2013). Mostly these diseases 
share a common link that tau proteins are hyperphosphorylated and form cytoplasmic 
inclusions in both neurons and glia (Lee, Goedert, & Trojanowski, 2001). The tau 
isoforms found in the aggregates vary depending on the tauopathy. In Alzheimer’s 
disease, both 3R and 4R tau aggregates are observed (Buée & Delacourte, 1999). 
However, only 4R tau aggregates are found in progressive supranuclear palsy and only 
3R tau fibrils exist in Pick’s disease (Buée & Delacourte, 1999). Mutations in tau gene 
lead to frontotemporal dementia with Parkinsonism- linked to chromosome 17 (FTDP-
17). These mutations reduce the ability of tau to interact with microtubules and also 
promote the assembly of tau into filaments (Hasegawa, Smith, & Goedert, 1998; 
Spillantini & Goedert, 2013). Since the production of 3R and 4R tau isoforms depend on 
the alternative splicing of mRNA, tau gene mutations connected to exon 10 result in the 
overproduction of 4R tau in comparison to the 3R and the assembly of 4R tau into 
filaments (Hasegawa, Smith, & Goedert, 1998; Spillantini & Goedert, 2013).  
1.3.3 Tau fibrillization in vitro  
Tau filaments are detected in all Alzheimer’s patients. Tau monomers clump 
together forming highly organized phosphorylated filaments (Grundke-Iqbal et al., 1986; 
Berriman et al., 2003). The aggregation occurs among the tandem repeats forming a 
stable core in tau filaments (Wischik et al., 1988a; Novak, Kabat, & Wischik, 1993). The 
molecular mechanisms of tau assembly into insoluble aggregates in the brain remain 
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unsolved. In vitro, the assembly of recombinant tau into fibrils has been achieved (De 
Garcini, Serrano, & Avila, 1986; Goedert et al., 1996). PHFs that are isolated from 
Alzheimer’s disease brain have the same morphology as the fibrils formed in vitro 
(Wischik et al., 1988b). Tau is an intrinsically disordered protein and its folding is 
unfavorable (Mandelkow & Mandelkow, 2012). The amino acid sequence of tau makes it 
positively charged, therefore using negatively charged cofactors will accelerate 
aggregation. The aggregation occurs due to the electrostatic interaction between the 
positive charge of tau and the negative charge of a cofactor (Calamai et al., 2006). A 
variety of negatively charged molecules can be used as cofactors. Polyanions such as 
heparin, RNA and polyglutamic acid are utilized to form tau filaments (Goedert et al., 
1996; Kampers et al., 1996). In addition, some fatty acids like arachidonic acid can be 
used as cofactors (Wilson & Binder, 1997; King et al., 2000). In vitro, there are factors 
that lead to aggregation in the absence of a cofactor, such as urea treatment for 60 hours 
(De Garcini, Serrano, & Avila, 1986), high temperature (Luo et al., 2013), high salt 
(Crowther et al., 1994; Wille et al., 1992), certain mutations (Schweers et al., 1995), or 
incubation with high protein concentration (De Garcini, Serrano, & Avila, 1986; De 
Garcini et al., 1988).  
 The breakage of tau fibrils leads to smaller fragments, hereinafter referred to as 
tau seeds. The initial tau aggregates will be referred to as tau fibrils throughout the 
remainder of this manuscript. Tau seeds are proposed to enhance aggregation more 
efficiently than tau fibrils. The seeds are very efficient because new ends can be produced 
upon breakage to which additional monomer can be recruited, leading to enhance 
elongation (see section 1.2 and Figure 1.1). Understanding how aggregates are formed 
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upon the addition of seeds to monomeric tau helps gain more insight into these 
aggregates. Both the 3R and 4R versions of tau seeds (K18 and K19) accelerate tau 
assembly (Dinkel et al., 2011). Cross seeding for truncated tau shows K19 seeds could 
seed K18 monomer. However, K19 monomeric tau cannot grow on K18 sonicated seeds 
(Dinkel et al., 2011). The seeding efficiency of full-length tau (hTau40 and hTau23) was 
investigated in this research. 
1.3.4 Tau fibril propagation 
 Recent experimental studies have implicated that protein aggregates associated 
with Alzheimer’s, Parkinson’s and Huntington’s diseases are capable of spreading, 
possibly in prion-like manner, from affected to unaffected regions in the brain. (Lee et al., 
2011; Brundin, Melki, & Kopito, 2010; Goedert, Clavaguera, & Tolnay, 2010). In 
Alzheimer’s disease, tau fibrils can spread throughout the brain as the disease progresses 
(De Calignon et al., 2012). There are six different stages in Alzheimer’s disease that 
represent the progressive spread of fibrils (Braak & Braak, 1991; Braak & Braak, 1996). 
Fibril formation begins in the transentorhinal cortex in the earliest stage of Alzheimer’s 
and spreads to the hippocampus and the neocortex as the disease progresses (Braak & 
Braak, 1991). In vivo, the injection of mouse brain extract that contains fibrils into 
healthy mouse brain resulted in the enhancement of tau assembly and the spread of tau 
aggregates from the injected regions to the anatomically linked brain regions (Liu et al., 
2012; Clavaguera et al., 2009; Clavaguera et al., 2013b). Since tau fibrils are intracellular 
deposits and not extracellular, some work has been performed to understand the 
mechanism of tau aggregate transmission from the outside to the inside of the cell (Santa-
Maria et al., 2012; Holmes & Diamond, 2012; Kfoury et al., 2012; Frost, Jacks, & 
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Diamond, 2009). Studies have shown that tau fibrils made of recombinant tau and tau 
fibrils from the brains of patients with Alzheimer’s disease are capable of being taken up 
by cells (Spillantini & Goedert, 2013; Frost, Jacks, & Diamond, 2009). Tau fibrils are 
capable of altering monomeric tau in another newly affected cell into aggregates (Iba et 
al., 2013; Clavaguera et al., 2013a; Frost, Jacks, & Diamond, 2009). A study 
demonstrated the effect of aggregate size on their transmission through the cells. Small 
aggregates and short fibrils (10-100 nm) are able to be endocytosed by neurons; however, 
the long and high molecular weight fibrils, in addition to monomeric tau, are not (Wu et 
al., 2013). Therefore, in order to understand how tau fibrils might spread through the 
brain of tauopathy patient, this study has focused on mechanisms that could break long 
tau fibrils into shorter ones. Heat shock proteins could offer such a mechanism. 
1.4 Chaperones 
Molecular chaperones are any proteins which interact and assist other proteins in 
the cell to fold correctly without being included in the protein final functional structure 
(Hartl, 1996). In addition, molecular chaperones play a role in a cell’s proteostasis by 
refolding stress denatured-proteins, facilitate protein degradation and aggregate 
disassembly (Kim, Y et al., 2013). Many chaperones are considered to be heat shock 
proteins (HSPs) (Hartl, 1996). HSPs are produced by cells in response to exposure to 
severe conditions like high temperature and stress. Some of the most studied HSPs are 
HSP104, HSP110, HSP90, HSP70 and HSP40 (Kim, Y et al., 2013). The nomenclature 
of HSPs is based on the molecular weight of the protein. For example, HSP90 is 90 kDa 
in molecular weight. HSPs demonstrate aggregate clearance ability by either inhibiting 
aggregation or fibril disassociation (Hartl, Bracher, & Hayer-Hartl, 2011). Therefore, the 
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assessment of the effects of molecular chaperones on tau aggregates might provide a tool 
for monitoring disaggregation. Some of the heat shock proteins belong to the AAA+ 
superfamily of ATPase, such as HSP104. 
1.4.1 HSP104 
HSP104 is a hexameric AAA+ protein from yeast that is associated with the 
protection of proteins from damage caused by elevated temperature or severe stress 
(Grimminger‐Marquardt & Lashuel, 2010). HSP104 assists yeast cells in recovery after 
being subjected to high temperatures or stress (Doyle & Wickner, 2009). Without 
HSP104, yeast loses its ability to dissociate aggregates. A mutation of the HSP104 gene 
causes yeast cells to lose their ability to recover from extreme temperature and stress 
effects (Doyle & Wickner, 2009). HSP104 demonstrates the ability to increase the cell 
subsistence up to 1000-fold when the cells are exposed to a temperature of 55°C 
(Lindquist et al., 1995). Even though HSP104 plays an essential role in cell survival, the 
functions of HSP104 are not enough for cells to survive (Weibezahn et al., 2004). Under 
normal growth conditions HSP104 plays a role in the formation and propagation of prion 
(Grimminger‐Marquardt & Lashuel, 2010). HSP104 has a bacterial homologue termed 
Caseinolytic Peptidase B protein (CLpB) (Doyle & Wickner, 2009). Moreover, HSP104 
has a homologue in plants, fungi, protozoa and chromista (Queitsch et al., 2000; 
Cavalier-Smith, 2004,). However, there is not a metazoan homologue for HSP104 
(Doyle, Genest, & Wickner, 2013).  
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1.4.2 The relevance of HSP104 
In yeast, HSP104 is the protein responsible for breaking the large fibrils into 
shorter fibrils that acquire the ability to be transmitted between the mother and daughter 
cells (Romanova & Chernoff, 2009; Winkler et al., 2012b; Liebman & Chernoff, 2012; 
Satpute-Krishnan, Langseth, & Serio, 2007). These seeds serve as templates for the 
recruitment of additional prion Sup35 monomers (Winkler et al., 2012a). Tau propagation 
is thought to function in a prion-like manner. It has been shown that cells can take up 
only short fibrils and small aggregates (Wu et al., 2013). The biological mechanisms that 
lead to fragment tau fibrils into smaller aggregates are not known. Since mammalian cells 
do not possess an HSP104 homologue, it is possible that another chaperone system or 
clearance-related mechanisms lead to fibril fragmentation. In this work, yeast HSP104 
was used as a model system to test whether we can monitor fracturing. Sonication breaks 
fibrils into smaller aggregates that enhance aggregation. Hence, it was hypothesized that 
breakage of tau fibrils by HSP104 would produce seeds that accelerate tau aggregation. 
Thereafter, a similar assay could be used with mammalian extracts to search for 
functional equivalents of HSP104 in mammalian cells. 
1.4.3 HSP104 activity on amyloid fibrils 
HSP104 is unique since it is one of only a few chaperones that has the ability to 
resolubilize already aggregated proteins (Doyle, Genest, & Wickner, 2013). HSP104’s 
functional structure gives it the feature of disaggregating and refolding misfolded 
polypeptides (Wendler et al., 2009). As an AAA+, HSP104 forms a tiered two-ring 
hexamer shape in the presence of ATP, which consists of 6 protomers (Parsell, Kowal, & 
Lindquist, 1994). HSP104 is believed to disassemble aggregates by extracting the 
	  14 
polypeptides chain from the aggregates and translocating it through the axial channel of 
HSP104 hexamer (Franzmann, Czekalla, & Walter, 2011; Wendler et al., 2009; Wendler 
et al., 2007). The efficiency of HSP104 to dissolve fibrils is promoted by collaboration 
with the co-chaperones (HSP70 and HSP40) or small heat shock proteins (DeSantis et al., 
2012; Torrente & Shorter, 2013). This system of HSP104, HSP70 and HSP40 was shown 
in yeast and bacteria to mediate disassembly of aggregated protein. In vitro, yeast 
HSP104 can disaggregate highly stable amyloid fibrils of Aβ, tau, polyglutamine, and 
amylin (DeSantis et al., 2012). HSP70 could play a role at the beginning of the protein 
remodeling process by extracting the polypeptides from the aggregate and passing it 
through HSP104’s axial channel. In case of folded proteins, HSP70 could play an 
important role after the polypeptide is already passed through the HSP104 cavity by 
assisting the unfolded proteins to fold correctly (Doyle & Wickner, 2009; Tessarz, Mogk, 
& Bukau, 2008; Glover & Lindquist, 1998). The ability of either HSP104 alone or in 
conjunction with HSP70 and HSP40 to process tau fibrils was examined in this thesis.  
1.5 Thesis rationale and objective 
 This study was conducted to assess the effects of the yeast chaperone, HSP104, 
on tau fibrils. These effects were: fibril breakage, fibril dissociation and tau aggregation 
inhibition. Previous studies implicated the ability of HSP104 to dissociate amyloid fibrils. 
Furthermore, HSP104 was shown to break large aggregates into smaller pieces. In this 
work, HSP104 was used as a model system to determine if tau fibril breakage can be 
monitored. We first investigated the effects of breakage on the seeding properties of tau 
fibrils. We formed tau fibrils with or without using a cofactor and then the fibrils were 
sonicated to produce smaller fragments (seeds). Next, we compared seeding properties of 
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the sonicated tau fibrils to the non-sonicated ones. In order to evaluate the seeding 
properties, we used a fluorescence assay and sedimentation. HSP104, either alone or with 
HSP70 and HSP40, was applied to tau fibrils. The seeding property of the fibrils was then 
assessed; since if any breakage occurred, this would be reflected on the enhancement of 
tau aggregation. The seeding assay was also used to evaluate the ability of HSP104 to 
suppress tau fibril elongation. Finally, fibril dissociation by HSP104 alone or in 
conjunction with HSP70 and HSP40 was evaluated by sedimentation of fibrils. 
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Chapter 2: Materials and Methods 
2.1 HSP104 plasmid transformation/amplification 
The DNA of HSP104, in pET28b (4 µg), was purchased from BIOMATIK. This 
plasmid produces HSP104 with His6-tag at its amino terminus. Plasmid was transformed 
into XL1 Blue Supercompetent cell lines (Strategene kit). Two microliter of the DNA 
was added to 17 µl of XL1 Blue competent cells in polypropylene tubes (14-ml Falcon 
round bottoms) and kept on ice for 30 minutes. The cells were heat shocked by placing 
the tube in a water bath (VWR Scientific model 1141) at 42°C for 50 seconds. They were 
then placed on ice for two minutes. 800 µl of NZY (Appendix A) + (10 g/L NZ-amine, 
12.5 mM MgSO4, 12.5 mM MgCl2 and 20 mM glucose) was added to the sample, 
incubated in a shaker for 40 minutes at 37°C and then plated onto kanamycin LB agar 
plates. The plasmid was then purified by Qiagen® Plasmid Midiprep Kit and stored in a 
freezer at -80°C. 
2.2 Chaperone transformation  
Plasmids carrying the genes for HSP104, HSP70, or HSP40 were transformed 
into Escherichia coli (E.coli) BL21-DE3. Chaperone DNA (1.5 µl) was added to 17 µl of 
the E.coli BL21-DE3 (Agilent) and incubated at 4°C for 30 minutes (using polypropylene 
tubes 14-ml Falcon round bottoms). The tube was placed in a water bath at 40°C for 50 
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seconds and immediately placed on ice for two minutes. 800 µl of NZY (Appendix A) + 
(10 g/L NZ-amine, 12.5 mM MgSO4, 12.5 mM MgCl2 and 20 mM glucose) was 
subsequently added and followed by incubation in a shaker for 40 minutes at 37°C. After 
incubation, 50 µl of the bacteria mixture was plated gently on LB agar. The plates with 
the bacteria were then incubated at 37°C overnight (14-16 hours). 
 The agar plates were made by adding 20 g of LB (Difco) and 15 g Agar/Miller 
(Fisher scientific) to one liter of DI water followed by autoclaving. The mixture was then 
allowed to cool down and then 50 mg of kanamycin were added. The mixture was placed 
on plates (Kord-Valmark) to solidify.  
2.3 Chaperone expression and purification 
Chaperones were expressed as previously described (Schirmer & Lindquist, 
1995). Chaperone was expressed in Escherichia coli (E.coli) strain BL21-DE3 (Agilent). 
An overnight culture was prepared by adding a single bacterial colony and 41 µM 
kanamycin to 50 ml LB Miller and incubated at 37°C overnight (14-16 hours). Next, 15 
ml of the bacteria from the overnight culture was added to 1.5 L of LB and 41 µM 
kanamycin. The mixture was incubated in a shaker at 37°C. When the optical density at 
wavelength 600 nm measured between 0.8 and 1.0, (requiring approximately 3 hours), 1 
mM IPTG (Gold Biotechnology) was added to induce protein expression. This was kept 
in the incubator for 3.5 additional hours and then was spun down for 15 minutes at 3,800 
x g. The pellet was resuspended in buffer (50 mM Tris, pH 7.4, 0.8 mM Imidazole, 500 
mM NaCl) and stored at -80°C. 
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The bacteria were thawed at room temperature and subsequently lysed by adding 
a small spatula tip of 4T lysozyme (Sigma) (final concentration approximately 20 mg/L 
lysozyme), 1% X Triton X-100 and DNase (Sigma). The samples were incubated for 30 
minutes in a shaker at 4°C and were then continuously sonicated for one minute at 50% 
amplitude. They were immediately pelleted at 15,000 x g for 30 minutes to remove cell 
debris, and supernatant was kept. Lysates containing histidine tagged proteins were 
applied to nickel affinity chromatography. Two ml of Ni-Sepharose beads (Qiagen) were 
added to the supernatant and incubated at 4°C for one hour. Ni-Sepharose beads were 
collected and washed with five column volumes of buffer (50 mM Tris, pH 7.4, 0.8 mM 
Imidazole and 500 mM NaCl) and proteins were eluted with buffers containing different 
imidazole concentrations (100 mM, 200 mM, 400 mM, 800 mM). The flow through was 
collected and analyzed by SDS-PAGE with broad range marker (BRM), from (BIO-
RAD) as the standard. The gels were stained using Coomassie blue dye and then 
destained using Destain solution (Appendix A) (Figure 2.1). The fractions that had the 
chaperone were combined and then were placed into dialysis tubings (Spectra/Por 
MWCO: 6-8,000) and dialyzed for two hours against the buffer (20 mM Tris, pH 7.4, 80 
mM NaCl, 1 mM DTT, 1 mM EDTA). Since HSP40 precipitated at 80 mM of NaCl, the 
salt concentration was increased to 350 mM, which prevented precipitation. Samples had 
been incubated overnight at 4°C. 
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Figure 2.1: SDS-PAGE analysis of fractions eluted from the nickel affinity 
chromatography step. The supernatants of lysed cells were incubated with 2 ml of    Ni-
Sepharose beads. Bound proteins were eluted with 2 ml of elution buffer containing 
different concentrations of imidazole (100, 200, 400 and 800 mM, respectively). 
Fractions of HSP104 (A), HSP70 (B) and HSP40 (C) were collected and analyzed by 
SDS-PAGE.  
 
	    
(B) 
(C) 
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The pooled fractions were syringe filtered using GxF/0.45 µm GHP and were then 
applied onto a Superdex 200 gel filtration column (GE Healthcare) in buffer 100 mM 
NaCl, 20 mM HEPES, pH 7.4, 0.5 mM EDTA, and 2 mM DTT for HSP104 and HSP70, 
and 100 mM NaCl, 20 mM PIPES, pH 6.5, 0.5 mM EDTA, and 2 mM DTT for HSP40. 
The fractions were collected according to the absorbance peaks at 280 nm (Figure 2.2). 
Peak fractions were analyzed by SDS-PAGE (Figure 2.3). To further purify the 
chaperone samples, the pooled fractions of HSP104 and HSP70 were applied onto a 
Mono Q 10/100 anion exchange column (GE Healthcare), and HSP40 was applied onto a 
Mono S 10/100 cation exchange column (GE Healthcare). The proteins were eluted with 
a 50 mM- 1000 mM NaCl gradient (buffer B) (Figure 2.4). The fractions with UV 
absorbance peak were collected and analyzed by SDS-PAGE (Figure 2.5). Proteins were 
then aliquoted and flash frozen with liquid nitrogen and stored at -80°C.  
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Figure 2.2: Size exclusion chromatography of purified chaperone proteins. The 
proteins eluted using a Superdex 200 size exclusion column, and each fraction was 5 ml. 
Each sample showed a single peak corresponding to the protein. Fractions of chaperone 
proteins were pooled according to the peak, (A) HSP104 39-48 fractions, (B) HSP70 
fractions 43-49, and (C) HSP40 fractions 46-54. 
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Figure 2.3: SDS-PAGE analysis of chaperone samples after being purified by size 
exclusion chromatography. The collected fractions from FPLC were applied to 12% 
SDS-PAGE gel and protein bands were detected by staining the samples with Coomassie 
blue. (A) Fractions of HSP104 from 39 to 48 were collected. (B) The collected fractions 
of HSP70 were 43-45. (C) HSP40 fractions from 50 to 54 were collected. 
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Figure 2.4: Ion exchange chromatography of chaperone proteins. The proteins were 
eluted with a 50 mM- 1000 mM NaCl gradient (buffer B) shown in yellow. Each elution 
fraction was 3 ml. Mono Q anion exchange chromatography was used with HSP104 and 
HSP70. (A) The collected fractions of HSP104 were 24-28 according to the absorbance 
peak. (B) The fractions 6-11 were pooled for HSP70. (C) HSP40 was purified using 
Mono S cation exchange chromatography and a double peak presented, therefore, the 
fractions 23-32 were collected and applied onto SDS-PAGE gel.  
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Figure 2.5: SDS-PAGE analysis of chaperone protein fractions obtained by ion 
exchange chromatography. The purity of pooled fractions was analyzed by SDS-PAGE. 
(A) HSP104 fractions 25-27 were pooled. (B) Fractions 8-10 of HSP70 were collected. 
(C) Fraction 24 was the only one chosen for HSP40 as it was the purest. 
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2.4 Tau protein expression 
Full-length tau (hTau23, hTau40) and truncated tau (K18, K19) were expressed 
and purified as described previously (Margittai & Langen, 2006). Four repeat tau has two 
natural cysteines in the second and third repeat, while three repeat tau has one cysteine in 
the third repeat region. In previous work from the Margittai lab, the native cysteine had 
been replaced by a serine using site-directed mutagenesis using the QuikChange method 
provided by Stratagene/Agilent Technologies. All DNA sequences were confirmed by 
DNA sequencing. 
The same procedure was followed for DNA transformation as mentioned in 
section 2.2. Tau was expressed in Escherichia coli (E.coli) strain BL21-DE3 (Agilent). 
An individual colony was picked from the LB agar plates, or scraped from a glycerol 
stock, and added to 50 ml of LB media with 41 µM kanamycin. It was then incubated in a 
shaker at 37°C for 16 hours. Fifteen ml of the prepared bacteria and 41 µM kanamycin 
were added to 1.5 liters of LB miller (Difco) and placed in a shaking incubator at 37°C. 
The optical density was measured at 600 nm and as soon as it reached 0.8 -1.0, 1.0 mM 
IPTG was added to the bacteria to induce protein expression. The bacteria were incubated 
for another 3.5 hours followed by centrifugation for 15 minutes at 3,800 x g. This 
produced pellet of bacteria was resuspended in buffer (500 mM NaCl, 20 mM PIPES, pH 
6.5, 5 mM EDTA and 50 mM of β-mercaptoethanol) and stored at -80°C until the next 
step of purification. 
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2.5 Tau protein purification 
The bacterial suspension was taken from the freezer and heated to 80°C in a water 
bath for 20 minutes followed by cooling the samples on ice for 5 minutes. In order to 
break the cell walls, the bacterial samples were continuously sonicated for one minute at 
50% amplitude using a Fisher scientific sonicator. The sonicated samples were pelleted at 
15,000 x g for 30 minutes. The supernatant was kept because it had the protein, whereas 
the pellet that contained cellular components was disposed of. In order to precipitate 
protein, 56% w/v of ammonium sulfate was added to the supernatant and kept rocking for 
an hour at room temperature. Thereafter, the sample was spun down for 10 minutes at 
15,000 x g. The pellet was suspended in 50 ml of cold dH2O containing 2 mM 
Dithiothreitol (DTT). The suspension was continuously sonicated for 30 seconds at 50 % 
amplitude. Next, the suspension was directly syringe filtered using GxF/0.45 µm GHP 
membrane (Pall Life Science) and then was applied onto a Mono S 10/100 GL cation 
exchange column (GE Healthcare) in 50 mM NaCl, 20 mM PIPES, 0.5 mM EDTA and 2 
mM DTT, pH 6.5 buffer. The instrument used for tau purification was AKTA design GE 
Healthcare Fast Protein Liquid Chromatography (FPLC). The proteins were eluted with a 
50 mM- 1000 mM NaCl gradient (buffer B). Based on the elution profile, fractions 11-17 
were collected (Appendix B) and analyzed using SDS-PAGE (Appendix B). To achieve 
that, 6 µl of the protein was mixed with 2 µl of 4X sample buffer and loaded onto 12% 
SDS-PAGE gel for full-length tau, and 15 % for truncated tau. A broad range marker 
(BRM) from (BIO-RAD) was used as a standard. The gels were stained using Coomassie 
blue dye and then destained using Destain solution. The pooled fractions were applied 
onto a Superdex 200 gel filtration column (GE Healthcare) in 100 mM NaCl, 20 mM 
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Tris, 1 mM EDTA and 2 mM DTT, pH 7.4 buffer, and the protein fractions were 
collected (Appendix B). Pooled tau fractions were precipitated overnight at 4°C by the 
addition of an organic solvent. An equal volume of methanol with 5 mM DTT was added 
to the pooled fractions of full-length tau. For the pooled fractions of truncated K18 and 
K19, a 4-fold volumetric excess of acetone with 5 mM DTT was added. Precipitated tau 
was pelleted at 11,000 x g for 25 minutes. Protein pellets were washed in methanol for 
full-length tau or in acetone for truncated K18 and K19, with 2 mM DTT and stored at     
-80°C.  
2.6 Acrylodan labeling of tau 
A single cysteine tau pellet (roughly 4-6 mg) was dissolved in 200 µl of 8 M 
guanidine hydrochloride (Thermo Scientific). Acrylodan was attached to a single cysteine 
(Figure 2.6) by the addition of 10-fold molar excess of acrylodan (Invitrogen) and 
incubated for an hour at room temperature. In order to remove free acrylodan and 
guanidine hydrochloride, the protein sample was passed through a PD-10 desalting 
column (GE Healthcare) with 100 mM NaCl, 0.1 µM NaN3, 10 mM HEPES, pH 7.4 
buffer. Cysteine-free proteins followed the same procedure but no acrylodan label was 
added after dissolving tau pellet in guanidine hydrochloride. The protein concentration 
was measured using BCA assay (Pierce).  
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Figure 2.6: Tau acrylodan label. Tau with a single cysteine was labeled by acrylodan at 
position 310. 
 
2.7 Tau seed preparation 
Tau fibrils were formed by incubating 20 µM of tau with 40 µM of heparin 
(average molecular mass of 5000 Da, Celsus, Cincinnati, OH) under stirring conditions at 
room temperature (25°C) for eight days for full-length tau and three days for truncated 
tau. In case of tau assembly without cofactor, 20 µM of tau was incubated under stirring 
conditions at 37°C for eight days. To prepare tau seeds, 500 µl of the fibrils were 
removed and continuously sonicated with a microtip using a Fisher Scientific Sonifier 
(Model 100) for 20 seconds at 20% amplitude.  
Tau fibrils were also formed under quiescent conditions. Tau seeds at the 
concentration of 0.8 µM were added to 10 µM monomeric tau and two-fold excess of 
heparin (20 µM) in buffer (10 mM HEPES, pH 7.4, 100 mM NaCl, 0.1 µM NaN3). The 
mixture was incubated at 37°C for 16 hours without agitation. The fibrils then were 
continuously sonicated for 20 seconds at 20% amplitude to produce seeds. 
Acrylodan 
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2.8 Electron microscopy 
 Electron microscopy (EM) was used in order to verify the fibrillar nature of the 
proteins. The 250-mesh carbon coated grid was placed on 10 µl drops of tau fibrils (based 
on monomer concentration) for 40 seconds, and then negatively stained by placing the 
grid on 10 µl of 2% uranyl acetate for 40 seconds followed by air-drying on filter paper. 
The sample was imaged using a Philips/ FEI Tecnai-12 electron transmission microscope 
that had a Gatan 2k x 2k CCD camera. The instrument was available at the University of 
Colorado, School of Medicine. 
2.9 Acrylodan seeding assay 
 In all reactions, 10 µM tau monomer that consisted of 2% acrylodan labeled tau 
with a single cysteine at the position 310 and 98% of cysteine-free tau (cysteines replaced 
with serines) was used. In addition, two-fold excess of heparin (20 µM) was added as a 
cofactor. All reactions were carried out in 100 mM NaCl, 10 mM HEPES, 0.1 µM NaN3, 
pH 7.4 buffer. The reaction was initiated by the addition of either seeds or tau fibrils, 
ranging from 0% - 8% (monomer equivalents). Temperature was controlled at 37°C using 
a solid state Pelletier element. The fluorometer used was the Fluorolog 3 system 
(Horriba, Jobin) fluorometer. The excitation wavelength was at 360 nm and the emission 
was measured from 400 nm to 600 nm for this fluorophore. The slit width for the 
measured excitation and emission were 5 nm. 
2.10 Sedimentation assay 
Tau seeds or fibrils were added to tau monomer (10 µM) and 20 µM of heparin 
and were incubated at 37°C for two hours. In some reactions; heparin was not added. The 
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mixture was pelleted at 100,000 x g for 30 minutes. The supernatant was removed and 
the pellet was washed with 1 ml of the buffer (10 mM HEPES, pH 7.4, 100 mM NaCl 
and 0.1 µM NaN3) and spun down at 100,000 x g for 10 minutes. The pellet was 
suspended in 60 µl 1X SDS-PAGE sample buffer and loaded onto 12% SDS-PAGE gel. 
The gel was stained using Coomassie blue and then destained using Destain solution 
(Appendix A). 
2.11 Fibril elongation inhibition assay 
 The inhibition of fibril elongation was assessed by acrylodan assay (section 2.9) 
and sedimentation analysis (section 2.10). Before adding tau seeds to the monomeric tau, 
10 µM of HSP104 was added to the mixture. 
2.12 Aggregation inhibition assay 
 Thioflavin T assay was used in order to detect the ability of HSP104 to inhibit 
aggregation of tau fibrils. Full-length tau (20 µM) was incubated with or without HSP104 
(10 µM) under stirring conditions for eight days at 37°C. The reactions were carried out 
in 100 mM NaCl, 10 mM HEPES, 0.1 µM NaN3, pH 7.4 buffer. In 96-well plates 
(Thermo Scientific), 5 µM of thioflavin T was added to 100 µl of tau samples at different 
time points. The fluorescence measurements were done using a Tecan Infinite M1000 
microplate reader with an excitation wavelength set at 440 nm and the emission 
wavelength at 480 nm. The excitation and emission slit widths were 5 nm.  
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2.13 Fibril breakage/dissociation assay 
Tau fibril dissociation was performed as described (Shorter, 2011). Tau fibrils    
(1 µM monomer equivalents) were incubated with the combination of HSP104 (10 µM), 
HSP70 (10 µM), HSP40 (10 µM), or only HSP104 (10 µM) in 40 mM HEPES, pH 7.4 in 
the presence of ATP (5 mM), ATP-regeneration system (25 µM creatine kinase and 1 
mM creatine phosphate) and MgCl2 (25 mM) for two hours at 37°C. In the breakage 
assay and after two hours incubation, tau monomer (10 µM) and heparin (20 µM) were 
added to the samples and incubated for two hours at 37°C. In some reactions; heparin 
was not added. Sedimentation assay was used to determine tau fibril dissociation and 
breakage by centrifuging the samples for 30 minutes at > 100,000 x g at 10°C, and the 
pellets were then washed with 1 ml of buffer. Pellets were dissolved in 60 µl of 1X SDS-
PAGE sample buffer and run on SDS-PAGE.  
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Chapter 3: Results 
3.1 Tau seeds accelerate aggregation of monomeric tau 
 The aggregation of many proteins is characterized by a lag phase which is the 
time required for nucleation to occur (Harper & Lansbury Jr, 1997). In general, amyloid 
fibril formation is enhanced by the addition of amyloid seeds that effectively overcome 
the lag phase (Arosio et al., 2013; Ovádi & Orosz, 2009; Nonaka et al., 2010). The seeds 
have the same properties of the original fibrils and act as templates onto which the 
monomeric proteins grow. To observe the breakage effects on the seeding properties of 
tau, fibrils were formed using heparin and sheared into smaller fragments (seeds). It was 
hypothesized that tau seeds enhance aggregation more efficiently than tau fibrils since the 
number of growth ends is multiplied upon breakage. Based on the finding in our lab that 
truncated tau fibrils (K18 and K19) enhance monomeric tau assembly when they are 
sheared (Dinkel et al., 2011), the seeding behavior of full-length tau fibrils was 
examined. The objective was to verify the effects of breakage on seeding and to compare 
it to the seeding properties of tau fibrils incubated with HSP104 that might have 
undergone breakage.  
Consequently, elongation kinetics were monitored using a fluorescence assay that 
depends on attached acrylodan sensing changes in the environment of the protein 
(Prendergast et al., 1983). Tau is intrinsically disordered and therefore tau is exposed to 
the aqueous solvent (Mukrasch et al., 2005; Cleveland, Hwo, & Kirschner, 1977). 
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Acrylodan was cross-linked to a cysteine of tau at position 310 in the third repeat. Tau 
monomer growth on the seeds is reflected by the changes of the monomer environments. 
Upon forming the fibrils, the third repeat that has acrylodan will be within the 
hydrophobic core region instead of being exposed to the polar solvent and that will be 
reflected by a blue shift (Margittai & Langen, 2004). All reactions included mixing 
acrylodan labeled tau with a 50-fold molar excess of cysteineless tau. The sample labeled 
with acrylodan was excited at 360 nm and the emission spectrum was measured from 400 
nm to 600 nm. In order to detect the monomer recruitment, acrylodan fluorescence 
maximum was monitored.  
In this reaction 10 µM hTau40 monomer consisted of 98% cysteineless tau 
(cysteines replaced with serines) and 2% acrylodan labeled tau. Before adding seeds, the 
acrylodan labels on tau monomers exhibited a maximum emission at 523 nm indicating 
exposure to solvent (Wearsch, Voglino, & Nicchitta, 1998). The addition of 8% hTau40 
seeds (monomer equivalents) and heparin (20 µM) initiated the aggregation of tau 
monomers, and the emission spectrum blue shifted over time to 467 nm, which reflects 
label exposure to a hydrophobic environment (Wearsch, Voglino, & Nicchitta, 1998). 
The shift of emission spectrum indicates the aggregation of tau monomers. The 
elongation kinetics of hTau40 were observed by plotting the reciprocal maximum 
wavelength as a function of time (Figure 3.1). Likewise, hTau23 demonstrated a blue 
shift when hTau23 seeds were added to monomeric tau (data not shown). The same 
experiment was run with the addition of unbroken tau fibrils instead of tau seeds. Tau 
fibrils enhanced the aggregation and produced similar seeding characteristics but with 
slower kinetics. The emission spectrum had a maximum at 523 nm and shifted to 467 nm 
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upon the addition of tau fibrils. The shift of the inverse emission wavelength during 
aggregation (seeded fibril formation) was plotted as a function of time for hTau40 
(Figure 3.1). The seeding competency of tau fibrils could be due to the stirring during the 
assembly process and hence fracturing of fibrils. Other findings suggested that stirring 
accelerates aggregation through fragmentation of the formed fibrils and generation of 
new ends (Serio et al., 2000). Aggregation of full-length tau (hTau40) occurred due to the 
addition of tau seeds and fibrils; however, in their absence there was not a shift in the 
spectrum (Figure 3.1). This suggests that monomer does not assemble spontaneously 
during the same time frame. The results are compatible with the data obtained for the 
truncated tau versions since K18 and K19 did not spontaneously form fibrils. Tau 
monomers require additional time to aggregate because nucleation has to occur first 
(Friedhoff et al., 1998).  
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Figure 3.1: Effects of sonication on tau seeding properties. Addition of 8% hTau40 
seeds or fibrils and 20 µM of heparin to 10 µM hTau40 monomers (98% cysteineless tau 
and 2% acrylodan labeled tau) results in a shift in the emission maximum from 523 nm to 
467 nm. Excitation: 360 nm, Emission: 400 nm – 600 nm. The inverse wavelength 
plotted as a function of time shows that tau seeds and fibrils enhance aggregation. 
Without an inclusion of seeds, no changes are observed. All values represent mean ± s.d. 
(n = 3 experiments). 
 
The procedure was modified in order to avoid breakage that might occur by 
stirring tau solution during assembly. The fibrils were formed under the usual conditions, 
and these tau fibrils were fragmented by continuous sonication at 20% amplitude for 20 
seconds to generate seeds. Then 8% seeds (monomer equivalents) were added to 10 µM 
tau monomer and 20 µM heparin and all were incubated at 37°C overnight without 
agitation. This method has the advantage of giving tau fibrils the ability to elongate 
without being fractured. The seeding properties of these unstirred fibrils were then tested 
by acrylodan assay following the same protocol. The addition of 0.5% tau seeds (hTau40, 
hTau23) caused a shift in the maximum emission of acrylodan from 523 nm to 462 nm 
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that reflected growth of monomers onto seeds. However, the addition of tau fibrils did not 
cause a shift in the emission maximum. From this data, it can be concluded that non-
fractured fibrils are inefficient in stimulating growth. Plotting the reciprocal maximum 
wavelength as a function of time indicates a difference between unstirred tau fibrils and 
tau seeds for both hTau40 and hTau23 (Figure 3.2). The overall measurements suggest 
that fibril breakage enhances the conversion of monomeric tau onto fibrils. 
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Figure 3.2: Effects of sonication on tau seeding properties. Seeded aggregation 
kinetics of unstirred tau fibrils were monitored using acrylodan assay. Addition of 0.5% 
tau seeds and 20 µM of heparin to 10 µM of tau monomer (98% cysteineless tau and 2% 
acrylodan labeled tau) results in a shift in the emission maximum from 522 nm to 462 nm 
for hTau40 and hTau23. In contrast, no changes are observed upon the addition of 0.5% 
tau fibrils. The inverse wavelength plotted as a function of time shows that fractured 
fibrils enhance aggregation of hTau40 (A) and hTau23 (B). All values represent mean ± 
s.d. (n = 3 experiments). 
 
3.2 HSP104 effects on tau fibrils  
The solubility of HSP104 during the experiment was examined. Typically, a 
buffer of 10 mM HEPES, pH 7.4, 100 mM NaCl was used. The pH dropped to 4 from 7.4 
as soon as the ATP was added and as a result HSP104 precipitated. Therefore, different 
A 
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concentrations of HEPES were applied to determine the proper concentration of HEPES 
necessary to prevent precipitation. At the concentration of 40 mM of HEPES, pH 7.4, 
HSP104 remained soluble and the solution was not affected by the addition of ATP.  
It was already reported that HSP104 is able to process amyloid aggregates either 
by itself or in combination with HSP70 system (HSP70 and HSP40) (Glover & Lindquist, 
1998; Shorter, 2011). Indeed, HSP104 has been shown to disassemble tau fibrils formed 
in vitro with arachidonic acid (DeSantis, 2012). Furthermore, HSP104 induces prion 
assembly by the breakage of fibrils and forming seeds (Paushkin et al., 1996; Shorter & 
Lindquist, 2006; Kryndushkin et al., 2003; Wegrzyn et al., 2001). Hence, we investigated 
whether or not HSP104 could dissociate or break tau fibrils that had been formed with 
heparin. First, tau fibril dissociation by HSP104 or the HSP104, HSP70 and HSP40 
system was tested. Dissociation of fibrils produces free soluble monomers, which 
decreases the aggregate concentration. This leads to a decrease in the band intensity of 
the sedimented material on SDS-PAGE gel. One micromolar of hTau40 or hTau23 fibrils 
(monomer equivalents) was incubated with 10 µM HSP104, 5 mM ATP and the ATP-
regeneration system (1 mM creatine phosphate and 0.25 µM creatine kinase). The 
mixture was incubated at 37°C for 2 hours in 40 mM HEPES, pH 7.4. As a control tau 
fibrils only were incubated under the same conditions. Thereafter, the samples were 
centrifuged at 100,000 x g for 30 minutes and the pellets were dissolved in 60 µl 1X 
SDS-PAGE sample buffer and analyzed by SDS-PAGE (Figure 3.3). Under the given 
conditions, HSP104 did not dissociate tau fibrils as the band of tau fibrils incubated with 
HSP104 and the control band were equivalent. Subsequently, the HSP70 system (HSP70 
and HSP40) was included. Previous work showed that HSP70 and HSP40 facilitate 
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HSP104 mediated fibril dissociation (Shorter, 2011). HSP104, HSP70 and HSP40 (10 
µM of each) were incubated with 1 µM of tau fibrils, ATP and the ATP-regeneration 
system. However, even the inclusion of HSP70/ HSP40 system did not facilitate 
dissociation by HSP104 and tau remained insoluble as shown in Figure 3.3.  
Next, the breaking competency of HSP104 was examined. It was shown that tau 
seeds enhance aggregation more effectively than long tau fibrils (section 3.1). We used 
the established seeding assay to determine if chaperones break tau fibrils into shorter 
fragments. This would be reflected in the enhancement of tau assembly. Tau fibrils (1 
µM) were incubated with either HSP104 (10 µM) only or HSP104 in combination with 
HSP70 system (10 µM of each) in addition to ATP and the ATP-regeneration system. 
After two hours of incubation, 10 µM of tau monomers and 20 µM of heparin were added 
to the mixture of tau fibrils and chaperones, and all were incubated at 37°C for two hours. 
As a control, the same procedure was applied to tau fibrils only. After two hours had 
passed, the mixture was spun down at 100,000 x g for 30 minutes and analyzed by an 
SDS-PAGE (Figure 3.4). If tau fibrils undergo breakage, added tau monomer would 
elongate on tau fibrils accompanied by an increased amount of insoluble tau. Therefore, 
the relative band on SDS-PAGE gel would be thicker. The gels did not demonstrate a 
significant difference associated with aggregation either with or without the addition of 
chaperones. Our results demonstrate that HSP104 might not be sufficient to break these 
fibrils.  
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Figure 3.3: Fibril dissociation by chaperones. Tau fibrils (1 µM monomer) were 
incubated for 2 hours at 37°C with HSP104 alone (10 µM) or in combination with HSP70 
and HSP40 (10 µM for each). Fibril dissociation of hTau40 (A) and hTau23 (B) was 
assessed by sedimentation analysis. The gel shows that tau fibrils remain insoluble, and 
the tau bands are similar whether chaperones are added or not.	  
 
 
 
 
 
 
 
 
Figure 3.4: Fibril breakage by chaperones. Tau fibrils (1 µM monomer) were 
incubated for 2 hours at 37°C with HSP104 alone (10 µM) or in combination with HSP70 
and HSP40 (10 µM for each). Fibril breakage of hTau40 (A) and hTau23 (B) was 
assessed by seeding assay using sedimentation analysis. Tau monomer (10 µM) and 
heparin (20 µM) were added to the fibrils and incubated for two hours. Samples were 
sedimented at 100,000 x g for 30 minutes and analyzed by SDS-PAGE and Coomassie 
staining. The SDS-PAGE gel shows bands with similar intensity indicating no 
preferential aggregation in the presence of chaperones. 	   	  
A B 
A B 
	  41 
3.3 Tau aggregates without a cofactor 
In the previous section, we showed that HSP104 in addition to the co-chaperones 
were not sufficient to either break or dissociate tau fibrils. Tau fibrils appear robust and 
hence not affected by chaperones. The aim of this experiment was to form tau fibrils at 
lower concentrations of heparin and possibly decrease the stability of the fibrils. As 
mentioned previously, tau assembly requires a cofactor such as heparin to accelerate 
aggregation (Goedert et al., 1996). In vitro, tau aggregation occurs due to the electrostatic 
interaction between the positive charge of tau and the negative charge of heparin 
(Calamai et al., 2006). It is thought that heparin might stretch along the fibril axis 
similarly to DNA binding to α-synuclein. Previous findings confirmed the ability of DNA 
to accelerate the assembly of α-synuclein and that DNA runs along the fibril axis (Cherny 
et al., 2004). Another study revealed that tau forms fibrils with and without heparin at 
high temperature; however, fibrils formed without heparin dissociate when cooled (Luo 
et al., 2013). Consequently, forming fibrils at lower concentrations of heparin might 
decrease the stability of fibrils. The usual ratio used for tau aggregation is 1:2 tau to 
heparin. Each of hTau40 or hTau23 (20 µM) was incubated with different heparin 
concentrations. The molar ratio of tau to heparin was 1:2, 2:1 and 4:1, respectively, and 
the samples were incubated for eight days at 37°C instead of 25°C. Tau was also 
incubated under the same conditions without adding a cofactor. After eight days of 
incubation, all samples were centrifuged at 100,000 x g for 30 minutes and the pellets and 
supernatants were then analyzed by an SDS-PAGE gel. Tau retains the ability to form 
aggregates even at lower concentrations of heparin for both isoforms. All tau proteins 
appeared in the pellet showing bands in SDS-PAGE gel, whereas the supernatant did not 
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contain tau (data not shown). Noteworthy, aggregation occurred even for the sample 
without a cofactor. That was not expected since it is thought that tau assembly requires a 
cofactor or other factors that facilitate aggregation as previously mentioned in Chapter 1 
section 1.3.3. Assembly of tau without a cofactor might be achieved due to the high 
temperature applied during fibrillization in addition to agitation. Consequently, further 
study of the properties of the formed tau aggregates without a cofactor was warranted. 
The formed aggregates of full-length tau were further examined to determine their 
morphology. EM was used to visualize the formed aggregates. The EM images for both 
of the full-length tau isoforms (hTau23, hTau40) indicated the formation of long and 
fibrillar aggregates that have an approximate width of 10 nm and varied length as shown 
in Figure 3.5. The aggregation kinetics of tau were monitored using thioflavin T 
fluorescence. Thioflavin T binds to amyloid fibrils and displays an enhanced fluorescence 
(Khurana et al., 2005). Both hTau40 and hTau23 monomer were incubated at 37°C 
without a cofactor for eight days. One-hundred microliter of the mixture was taken in 
addition to 5 µM of thioflavin and the fluorescence was measured. During the eight days 
of incubation, ThT fluorescence increased gradually representing the formation of tau 
aggregates (Figure 3.6). Data obtained from EM and thioflavin T fluorescence confirm 
the formation of filamentous tau in the absence of a cofactor. 
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Figure 3.5: Electron micrographs of tau fibrils. Tau monomer (20 µM) was incubated 
without a cofactor at 37°C under stirring conditions. The figure shows electron 
microscopy images of fibrils of hTau40 (A) and hTau23 (B). The scale bar represents 200 
nm. 
 
 
 
 
 
 
 
Figure 3.6: Tau aggregation kinetics were monitored by Thioflavin T fluorescence. 
Full-length tau monomer (20 µM) was incubated without a cofactor at 37°C under 
stirring conditions for eight days. 100 µl of tau sample (20 µM) was placed in microplate 
with 5 µM thioflavin T (ThT). Fluorescence emission was measured at 480 nm, with an 
excitation of 440 nm. Bars from left to right represent reactions after 1, 2, 7, and 8 days. 
The signal increases gradually indicating the formation of tau aggregates of hTau40 (A) 
and hTau23 (B). All values represent mean ± s.d. (n = 2 experiments).	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3.3.1 Tau seeds induce monomer recruitment 
In section 3.1, fractured tau fibrils were shown to accelerate the aggregation of tau 
monomers into fibrils. The seeding properties of tau fibrils formed without a cofactor 
were tested. Ultrasonic perturbation was applied to break fibrils into smaller aggregates 
that could be used to seed the aggregation of monomeric tau. Reactions were initiated 
with the addition of 8% tau seeds or fibrils to 10 µM tau monomer. As a control, seeds, 
fibrils and tau monomers were each incubated individually under the same conditions. 
Heparin was not included in these elongation experiments. After two hours of incubation 
at 37°C, all samples were centrifuged at 100,000 x g and the pellets were dissolved in 60 
µl of 1X SDS-PAGE sample buffer and applied on SDS-PAGE gels. It is clear that both 
hTau23 and hTau40 seeds have the ability to enhance tau aggregation; in contrast, tau 
fibrils do not (Figure 3.7). There was an increase of the band intensity that correlates with 
the growth of tau monomers on seeds. These results are similar to data observed for tau 
fibrils, which were formed with heparin (section 3.1), since their seeding ability was also 
increased upon sonication (Figure 3.2). The kinetics of elongation were monitored by 
fluorescence using the acrylodan assay. The labeled sample was excited at 360 nm and 
the emission spectrum was measured from 400 nm to 600 nm. The acrylodan 
fluorescence maximum was monitored. Ten µM of tau monomer (98% cysteineless tau 
and 2% acrylodan labeled tau) was incubated with tau seeds at 37°C. Before adding seeds 
to the monomer, acrylodan that labels tau monomer exhibited a maximum of 522 nm. 
Upon the addition of 8% seeds, the acrylodan emission was blue shifted to 467 nm for 
hTau23 seeds and 476 nm for hTau40 seeds, which indicates that monomers aggregated. 
On the other hand, there were no changes observed upon the addition of tau fibrils, which 
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means that tau fibrils did not enhance aggregation as well as seeds. The elongation 
kinetics of hTau40 and hTau23 were evaluated by plotting the reciprocal maximum 
wavelength as function of time (Figure 3.8). The obtained data corresponds to the results 
shown by sedimentation. Together our results present the effects of breakage of tau 
fibrils, and show that fractured fibrils promote tau fibrillization. 
 
 
Figure 3.7: Sonication effects on seeding properties of tau fibrils. The elongation of 
tau monomers on their homologue tau seeds was observed. Tau monomer (10 µM) was 
incubated with 8% seeds or fibrils at 37°C for two hours. Tau aggregation of hTau40 (A) 
and hTau23 (B) was assessed by sedimentation analysis. The greater band intensity 
reflects the growth of tau monomers on seeds. However, assembly of tau is not 
accelerated by tau fibrils. 
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Figure 3.8: Sonication effects on seeding properties of tau fibrils monitored by 
acrylodan assay. The sonication of tau fibrils generates seeds that were used in fibril 
elongation experiments. Addition of 8 % seeds to 10 µM tau monomer (98% unlabeled 
tau and 2% acrylodan labeled tau) causes a blue shift in the emission maximum from 522 
nm to 476 nm for hTau40 (A) and to 467 nm for hTau23 (B). In contrast, there is no shift 
upon the addition of tau fibrils. All values represent mean ± s.d. (n = 3 experiments).   
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3.3.2 HSP104 effects on tau fibrils 
            It has already been shown in section 3.2 that HSP104 alone or in combination 
with HSP70 and HSP40 is not sufficient to dissociate or break tau fibrils formed with a 
cofactor. It was hypothesized that forming fibrils without a cofactor might decrease the 
stability of fibrils. Sedimentation analysis was performed to evaluate fibril dissociation 
by HSP104. One micromolar of tau fibrils were incubated with 10 µM of each of three 
chaperones (HSP104, HSP70, HSP40) or without the chaperones as a control. The SDS-
PAGE analysis of the pellets showed that hTau40 and hTau23 fibrils remained insoluble 
demonstrating that fibrils did not dissociate (Figure 3.9). The breakage effect of HSP104 
on hTau23 and hTau40 fibrils was tested using seeding assay. It was shown in section 
3.3.1 that shearing fibrils produces small fragments that seed well, whereas unfractured 
fibrils do not. Tau monomer was added to the fibrils that had been incubated with 
chaperones. As a control, tau was added to fibrils that were not added to chaperones. The 
SDS-PAGE gels indicated that both fibril bands, in the presence and the absence of 
chaperones, were similar indicating that tau remained soluble and was not seeded (Figure 
3.10). These combined results show that HSP104 alone or in collaboration with HSP70 
and HSP40 was not sufficient to break or dissociate tau fibrils. Furthermore, the seeding 
assay might not be capable of monitoring the breakage of tau fibrils by HSP104, because 
fibril elongation was inhibited by HSP104. Hence, the effects of HSP104 on tau 
aggregation were investigated. 
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Figure 3.9: Fibril dissociation by chaperones. Tau fibrils (1 µM monomer equivalents) 
were incubated for 2 hours at 37°C with HSP104 alone (10 µM) or in combination with 
HSP70 and HSP40 (10 µM for each). Fibril dissociation of hTau40 (A) and hTau23 (B) 
was assessed by sedimentation analysis. The gel shows that tau fibrils remain insoluble, 
and the tau bands are similar whether chaperones are added or not.	  
 
 
 
 
 
 
 
 
 
Figure 3.10: Fibril breakage by chaperones. Tau fibrils (1 µM monomer equivalents) 
were incubated for 2 hours at 37°C with HSP104 alone (10 µM) or in combination with 
HSP70 and HSP40 (10 µM for each). Fibril breakage of hTau40 (A) and hTau23 (B) was 
assessed by seeding assay using sedimentation analysis. Tau monomer (10 µM) was 
added to the fibrils and incubated for two hours. Samples were sedimented at 100,000 x g 
for 30 minutes and analyzed by SDS-PAGE. The gel shows that no preferential 
aggregation occurred since the bands are approximately similar. 
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            Besides the ability of HSP104 to break and dissociate amyloid fibrils, HSP104 is 
also capable of inhibiting fibril elongation (Arimon et al., 2008). The seeding assay was 
used to determine the effects of HSP104 on tau fibril elongation. It was shown previously 
(section 3.3.1) that broken fibrils accelerates tau aggregation. The sedimentation assay 
was performed to clarify the HSP104 action. Seeds were added to tau monomer in either 
the presence or the absence of HSP104 and then incubated for two hours at 37°C. As a 
control, seeds, fibrils and tau monomers were each incubated individually under the same 
conditions. The mixtures were centrifuged and the produced pellets applied onto 12% 
SDS-PAGE gel. The gel demonstrated that HSP104 kept tau monomers soluble and 
blocked their growth (Figure 3.11). The acrylodan assay has also been used to evaluate 
HSP104 effects on tau fibril elongation following the same procedure as in section 3.2. In 
addition, 10 µM of HSP104 was added before the addition of tau seeds to the monomeric 
tau. The samples containing HSP104 blue-shifted from 522 nm to 513 nm and 502 nm for 
hTau23 and hTau40 seeds respectively, while the samples without HSP104 had a blue 
shift of the maximum emission to 467 nm for hTau23 and 477 nm for hTau40 (Figure 
3.12). The efficiency of HSP104 to inhibit elongation was higher when it was applied to 
3R tau fibrils. In conclusion, HSP104 prevents recruitment of tau monomers onto seeds 
and that suggests that HSP104 might bind to tau seed or tau monomers and prevent 
aggregation. In addition, the seeding assay was capable of determining the inhibitory 
effects of HSP104 on tau fibrils.  
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Figure 3.11: SDS-PAGE analysis of fibril elongation inhibition by HSP104. The 
aggregation of tau with or without HSP104 was assessed by sedimentation assay. 
Addition of 8% tau seeds to 10 µM tau monomers enhances the conversion of monomeric 
tau of hTau40 (A) and hTau23 (B) onto fibrils. However, when HSP104 (10 µM) was 
added, elongation was blocked.	  
 
 
 
 
 
 
 
 
 
 
 
A B 
Da   Da 
	  51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Tau elongation inhibition monitored by acrylodan assay. Tau seeds 
(8%) were added to 10 µM tau monomer (98% cysteineless tau and 2% acrylodan labeled 
tau) in the presence or absence of 10 µM HSP104. (A) Upon the addition of hTau40 
seeds, the emission maximum blue-shifted from 522 nm to 476 nm in the absence of 
HSP104 and from 522 nm to 502 nm in the presence of HSP104. (B) The addition of 
hTau23 seeds caused a blue shift of the emission maximum from 522 nm to 476 in the 
absence of HSP104 and from 522 nm to 513 nm in the presence of HSP104. Excitation: 
360 nm, Emission: 400 nm – 600 nm. The inverse wavelength plotted as a function to 
time shows that HSP104 prevents the elongation of tau fibrils. All values represent mean 
± s.d. (n = 3 experiments). Notice that the kinetics of tau aggregation in the absence of 
HSP104 was already presented in Figure 3.8. Here it is shown for comparative purpose 
only.	    
A 
B 
	  52 
3.3.3 HSP104 prevents tau assembly 
Full-length tau monomer demonstrates the ability to assemble without the 
addition of a cofactor and forms fibrils. HSP104 was reported to have some inhibitory 
effect on protein aggregation (Arimon et al., 2008; Lo Bianco et al., 2008); therefore, 
suppression of tau assembly by HSP104 was examined. The aggregation process was 
assessed using thioflavin T fluorescence. Ten micromolar of HSP104 was incubated with 
20 µM full-length tau monomer (either hTau23 or hTau40) and all incubated for eight 
days at 37°C under agitation. As a control, tau was incubated only without HSP104. 
Aliquoted samples of tau with or without HSP104 along the eight days of incubation 
were applied for measurement. At the beginning, the fluorescence emission values were 
approximately equal for both of the samples and it remained mostly constant for the first 
and the second day (Figure 3.13). As time passed, a variation in the emission intensity 
was noticed at day seven, and it went up for the sample that did not include HSP104. At 
day eight, there was a dramatic increase of the emission associated with the tau sample 
without HSP104 indicating that aggregation occurred (Figure 3.13). In contrast, the tau 
sample with HSP104 demonstrated a slight increase in the emission intensity through the 
eight days suggesting that aggregation was prevented by HSP104 (Figure 3.13). These 
results correspond to the findings that stated the ability of HSP104 to prevent the 
aggregation of Aβ and α-synuclein (Arimon et al., 2008; Lo Bianco et al., 2008). 
Together, HSP104 demonstrates an ability to prevent the conversion of monomeric tau 
into aggregates.  
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Figure 3.13: Monitoring the assembly suppression of tau fibrils by HSP104 using 
thioflavin T assay. Full-length tau (20 µM) was incubated with or without HSP104 (10 
µM) under stirring conditions for eight days at 37°C. 100 µl of tau sample (20 µM) was 
placed in microplate with an addition of 5 µM of thioflavin T. Fluorescence emission was 
measured at 480 nm, with an excitation of 440 nm. Bars from left to right represent 
reactions after 1, 2, 7, and 8 days. There was a significant increase in ThT fluorescence of 
hTau40 (A) and hTau23 (B) within the eight days of incubation. Upon the addition of 
HSP104, the signal was weak and did not increase as well as tau samples without 
HSP104. All values represent mean ± s.d. (n = 3 experiments).  
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Chapter 4: Discussion 
Tau accumulates and forms large neurofibrillary tangles that are the hallmark of 
more than 20 tauopathies (Spillantini & Goedert, 2013). To date, there is no therapy for 
these diseases. Since tau fibrils are associated with the progression of diseases, it was 
important to investigate the characteristics and mechanisms related to fibril formation and 
propagation. Even though tauopathies are not transmissible among organisms, previous 
studies indicated prion-like behavior of tau aggregates since fibrils are capable of 
spreading between cells (Brettschneider et al., 2015). The mechanisms by which 
aggregates can propagate from one neuron to the next remain unknown. A study 
confirmed that tau uptake is dependent on conformation and size of aggregates, since 
only small aggregates and short fibrils are taken up by cells and large fibrils are not (Wu 
et al., 2013). There has not been an observed mechanism that leads to fragmentation of 
large fibrils in mammalian cells. As a result, the breakage of fibrils into smaller 
fragments is the subject of ongoing investigation in order to determine the mechanism for 
how tau can enter cells. In yeast, HSP104 is essential to the mitotic stability of the prions. 
HSP104 is thought to fragment prions into seeds or propagons that are inherited to the 
next generation (Derkatch et al., 1997). However, a homologue of HSP104 has not been 
identified in mammalian cells. In this thesis, the effects of yeast chaperone HSP104 on 
tau fibrils have been investigated. HSP104 was used here as a model system to determine 
whether we can monitor tau fibril breakage. Our findings show that HSP104 inhibits tau 
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aggregation and fibril elongation, however, fibril breakage and dissociation by HSP104 
were not achieved. 
The mechanisms that initiate the assembly of soluble tau into aggregates remain 
unclear. Tau has high solubility and degree of disorder (Mandelkow & Mandelkow, 
2012). Previous studies have shown that non-phosphorylated full-length recombinant tau 
assembles into fibrils in vitro in the presence of negatively charged cofactors such as 
heparin, RNA and fatty acids (Spillantini & Goedert, 2013). In this study we formed tau 
fibrils at room temperature and the aggregation was induced using heparin. The results 
also indicated that tau monomers could assemble without a cofactor and form fibrillar 
aggregates. As shown by the thioflavin T assay, tau forms aggregates upon incubation at 
37°C for eight days under stirring conditions (Figure 3.6) and the presence of fibrilar 
structures was confirmed by EM imaging (Figure 3.5). In the absence of an inducer, prior 
studies indicate that tau does not aggregate spontaneously when incubated at 
physiological pH, temperature, ionic strength, and concentration (1–10 µM) (Kuret et al., 
2005). There are some factors that lead to the assembly of tau into fibrils in the absence 
of cofactor. These cofactors include urea treatment for 60 hours (De Garcini, Serrano, & 
Avila, 1986), high temperature (Luo et al., 2013), high salt (Crowther et al., 1994; Wille 
et al., 1992), certain mutations (Schweers et al., 1995), or incubation with high protein 
concentration (De Garcini, Serrano, & Avila, 1986; De Garcini et al., 1988). It is not fully 
understood why full-length tau aggregated in the absence of a cofactor in our study. 
Unlike some previous studies, tau fibrils were formed under agitation which may activate 
the self-assembly of tau. The agitation process that include stirring, sonication and 
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shaking was reported to induce amyloid fibril formation (Hill et al., 2006; Collins et al., 
2004; Serpell et al., 2000).  
The main effect of sonication is to fracture fibrils and increase the number of 
growth ends. We have taken a major a step toward our goal by establishing an assay 
demonstrating the enhancement of tau aggregation upon the addition of fractured fibrils. 
In our seeding experiments we have used the full-length tau hTau40 (4R) and hTau23 
(3R). Fibrils were sheared by applying ultrasonic perturbation, which leads to form 
shorter fragments (seeds). Our data generated by using the acrylodan assay (Figures 3.2; 
3.8) and sedimentation analysis (Figure 3.7), indicate that sonicated fibrils accelerated the 
conversion of monomeric tau into fibrils whereas non-sonicated fibrils did not. This was 
observed for both fibrils that were formed with or without using a cofactor. Our results 
are consistent with previous studies, which showed that amyloid formation is accelerated 
and lag phase is decreased upon the addition of seeds (Jarrett, Berger, & Lansbury Jr, 
1993; Kelly, 2000). A plausible explanation is that added seeds work as a nuclei that 
recruit tau monomers which lead to enhance aggregation. We also show that tau does not 
aggregate spontaneously in the same time frame window, since nucleation has to occur 
first (Figure 3.1). Therefore, we can be sure that the observed fibril growth is due to fibril 
elongation and not due to monomer nucleation.  
HSP104 was thought to break tau fibrils into smaller fragments that accelerate tau 
aggregation. This assumption is related in part to observations that HSP104 breaks large 
aggregates into smaller fragments (Glover & Lindquist, 1998; Parsell et al., 1994). 
Seeding assay was then used to investigate the effects of HSP104 on tau fibrils. Although 
Shorter and Lindquist showed that HSP104 alone can fragment fibrils (Shorter and 
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Lindquist, 2004), our results presented here indicate that HSP104 was unable to break tau 
fibrils that were formed with or without a cofactor (Figures 3.4; 3.10). Even the inclusion 
of HSP70 and HSP40 did not increase HSP104 activity any further. These results suggest 
that fibrils might have a distinct conformation that is highly stable and resists being 
broken either by HSP104 alone or in addition to HSP70 and HSP40. On the other hand, 
the seeding assay was capable of monitoring fibril elongation inhibition by HSP104. The 
data yielded by this study provides convincing evidence that HSP104 inhibits the 
elongation of tau fibrils and seeds were found to be unable to effectively recruit monomer 
(Figures 3.11; 3.12). It is hypothesized that HSP104 suppresses elongation by binding to 
the fibril ends and this action blocks growth. Our results are in agreement with previous 
literature that claimed that HSP104 prevents fibril elongation of α-synuclein and Aβ (Lo 
Bianco et al., 2008; Arimon et al., 2008).  
Furthermore this work shows that HSP104 prevents tau aggregation. Tau 
monomer represented an ability to aggregate without a cofactor at 37°C and form fibrils. 
Upon the inclusion of HSP104 during the fibrillization process, tau was soluble and did 
not aggregate (Figures 3.13). These results are in agreement with previous studies that 
stated the ability of HSP104 to prevent fibril formation of prions Sup35, Aβ and α-
synuclein (Arimon et al., 2008; Shorter, 2008; Lo Bianco et al., 2008). It is possible that 
HSP104 inhibits the aggregation during the nucleation phase since that was observed 
with prion Sup35 (Krzewska & Melki, 2006). HSP104 is very efficient at inhibiting 
aggregation. This might be due to its capability to interact with aggregation intermediates 
(Arimon et al., 2008). It is also possible that HSP104 binds to monomeric tau, which 
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would decrease the concentration of available tau and make aggregation less likely to 
occur.  
Since amyloid aggregates are associated with various neurodegenerative diseases, 
the mechanisms that mammalian cells rely on to clear aggregates were questioned in 
some pervious works. HSP104 possess an ability to resolubilize extremely stable amyloid 
fibrils. There is not a metazoan homologue of HSP104; however, it is possible that cells 
possess another chaperone system or operational mechanisms that correlate with 
aggregate dissociation. Some previous studies have tried to isolate a homologue of 
HSP104 in mammalian cells, however these attempts were unsuccessful (Mosser, Ho, & 
Glover, 2004). Tau fibril dissociation by HSP104 was investigated in this work. Our data 
show that HSP104 did not dissociate tau fibrils and fibrils remained insoluble, as the 
level of free monomeric tau did not change. The inclusion of HSP70 and HSP40, which 
promotes dissociation in prions, was not sufficient to achieve that with tau fibrils (Figures 
3.3; 3.9). In contrast to our results, it was previously shown that HSP104 is able to 
dissociate tau fibrils (hTau40 and K18) that were formed using arachidonic acid 
(DeSantis et al., 2012). While the reason of this discrepancy cannot be proven, it is 
possibly that the fibrils in this study have a distinct conformation that is highly stable and 
resists being dissociated, consistent with what was found when examining fibril 
breakage. 
4.1 Conclusion and future directions 
Any therapeutic strategy for tauopathies such as Alzheimer’s disease will 
certainly require a deep knowledge of tau aggregation, the pattern of aggregate growth 
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and fibril fragmentation. The primary objective of this research was to assess the effects 
of the yeast chaperone, HSP104, on tau fibrils. The effects of interest were: fibril 
breakage, fibril dissociation and tau aggregation inhibition. In this study, we collected 
data on tau aggregation by using the acrylodan assay and sedimentation analysis and 
conclusively demonstrated that fractured fibrils accelerated the conversion of monomeric 
tau into fibrils. Our results are consistent with previous studies, which showed that 
amyloid formation is accelerated and lag phase is decreased upon the addition of seeds 
(Jarrett, Berger, & Lansbury Jr, 1993; Kelly, 2000). The results obtained with HSP104 as 
a model system show that fibrils that were incubated with HSP104 (alone or with the 
inclusion of HSP70 and HSP40) did not accelerate the aggregation rate of tau. It is 
certainly possible that the tau fibrils have a distinct conformation that is highly stable and 
resists being broken or dissociated in contrast to the tau aggregate formed in the presence 
of arachidonic acid.  
Alternatively, it is possible that HSP104 was not efficient enough to break fibrils 
or that breakage occurred but was not detected due to the ability of HSP104 to block 
aggregation. Fibril breakage could be visualized by EM and that would be indicated by 
the presence of smaller fibrils, whereas dissociation would be reflected by the presence of 
fewer fibrils. These differences were observed with sonicated versus non-sonicated fibrils 
by using EM. Since it has been shown that HSP104 processes tau fibrils that were formed 
in vitro using arachidonic acid (DeSantis et al., 2012), the ability of HSP104 can be 
ensured following the same procedure. If the action of HSP104 is limited to specific kind 
of fibrils, different conformations of tau might explain the results. A recent work has 
developed re-engineered HSP104 variants that show a very high efficiency in comparison 
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to wild type HSP104 (Jackrel et al., 2014). These variants can be used in future work 
with the seeding assay to determine breakage of tau fibrils. If the re-engineered HSP104 
broke tau fibrils, then this assay could be used with mammalian extracts and hopefully 
assist in finding functional equivalents of HSP104 in mammalian cells.  
Tau shows an ability to aggregate in the absence of cofactor. While tau fibrils 
share in common the β-strand structure, the differences in the way β-sheets pack would 
lead to form different fibril conformations (Meyer et al., 2014). Tau fibrils are associated 
with more than 20 phenotypically distinct neurodegenerative diseases and the reason 
behind this diversity remains unclear (Frost et al., 2009). It was suggested that different 
fibril conformations could play a role (Frost et al., 2009). It was previously published that 
both tau and α-synuclein form fibrils with different conformations in vitro (Bousset et al., 
2013; Dinkel et al., 2011; Frost et al., 2009; Siddiqua & Margittai, 2010). Since the tau 
aggregates were formed at a higher temperature (37°C), the way tau monomers pack 
together could vary and therefore produce different conformations. A previous study has 
shown that heparin facilitates the aggregation of soluble tau into fibrils and also promotes 
fibril elongation (Zhu et al., 2010). Interestingly, heparin was not required for the 
elongation of fibrils that were formed in the absence of cofactor (Figures 3.7; 3.8). It is 
possible that fibrils formed in the absence of cofactor have different conformations that 
do not require heparin for the elongation. Further investigations are required to determine 
the conformation of fibrils formed without a cofactor and how they could differ with 
fibrils formed with heparin.  
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Appendix A 
Chaperone extraction buffer 
Tris (pH 6.5) 50 mM  
Imidazole 0.8 mM 
NaCl 500 mM 
 
Tau extraction buffer 
PIPES (pH 6.5) 20 mM  
EDTA (pH 8.0) 5 mM 
NaCl 500 mM 
 
Chaperone dialysis buffer A 
Tris  (pH 6.5) 40 mM  
DDT  1 mM 
NaCl 80 mM 
EDTA (pH 8.0) 1 mM  
 
Ion exchange buffer A 
PIPES  (pH 6.5) 20 mM  
DDT  2 mM 
NaCl 50 mM 
EDTA (pH 8.0) 1 mM  
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Ion exchange buffer B 
PIPES  (pH 6.5) 20 mM  
DDT  2 mM 
NaCl 1000 mM 
EDTA (pH 8.0) 1 mM  
 
Gel filtration buffer 
Tris  (pH 6.5) 40 mM  
DDT  2 mM 
NaCl 100 mM 
EDTA (pH 8.0) 1 mM  
 
Destain solution 
Methanol 50 ml 
Acetic acid 125 ml 
H2O 825 
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NZY 
NaCl 5 g 
MgSO4*7H2O  2 g 
Bacto-yeast extract 5 g 
NZ amine (Casein hydro 
lysate 
10 g 
Total volume 1 L 
pH  7.4 
 
1X SDS running buffer 
Glycine 190 mM 
Tris base 25 mM  
SDS 0.1 % 
 
Coomassie blue stain solution 
Coomassie  2.5 g 
Methanol 200 ml  
Acetic acid 50 ml 
H2O 250 ml 
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SDS-PAGE 4X Sample Buffer 
Reagent  Final Concentration Volume Mass 
80% Glycerol 40% 5 ml  
1M Tris-Cl, pH 6.8 240 mM 2.4 ml  
SDS 8%  0.8 g 
Bromophenol blue 0.1%  4 mg 
H2O  2.1 ml  
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Appendix B 
 
 
 
 
Cation exchange chromatography of full-length and truncated tau. A linear gradient 
elution of tau (green line) and each elution fraction is 3 ml. Blue line represents elution at 
280 nm. Fractions 13-17 were collected for further analysis and purification. 
  
K18 K19
hTau40 hTau23 
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Electrophoresis analysis of tau fractions pooled after being purified by FPLC. 
  
K18 K19
hTau40 hTau23 
   Da    Da 
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The fractions obtained from ion exchange chromatography were further purified using 
gel filtration. 
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hTau40 hTau23
